Associated Scientist

Prof. Dick de Zeeuw

Therapeutic Areas

  • Metabolic diseases

Useful Links

Dick de Zeeuw is Professor and Chair of the Department of Clinical Pharmacology at the University of Groningen, the Netherlands, with a joint appointment in the Department of Nephrology.

Theraputic areas and expertise

He earned his MD in 1975, and finished his PhD thesis in 1980 on the topic of renal hypertension. Dr de Zeeuw was trained in clinical and experimental renal research at the Renal Department in Groningen, and studied clinical pharmacology at the University of Dallas, Texas, USA in 1984-1985. He was Board Certified in 1996 at the University of Groningen.

Prof. de Zeeuw has served on the editorial boards of several international journals, including Kidney International, Journal of Hypertension, JRAAS, Current Opinion in Nephrology and Hypertension, Journal of Geriatric Urology and Nephrology, NEPHRON, Clinical Nephrology, and NDT Plus. He is Director of the Groningen University Institute for Drug Exploration (GUIDE), and a member of the ISN Council.

His research interests include optimising current therapeutic approaches and finding new ones to reduce the progressive loss of cardiovascular and renal function, both in diabetic and non-diabetic renal disease. A particular focus is on the role of albuminuria/proteinuria and microalbuminuria as biomarkers for cardiac and renal disease progression, investigating the independent causal role of albumin leakage in renal and cardiovascular disease progression, and establishing intervention strategies that reduce albuminuria/proteinuria.

Dick De Zeeuw has initiated large cohort studies such as PREVEND (general population) and GIANTT (type 2 diabetes), and is involved in the leadership of several clinical trials on preventing diabetic cardiovascular and renal progression such as RENAAL (AII-receptor antagonist), PLANET (statin), TREAT (EPO), VITAL (vitD), SUN (sulodexide), ALTITUDE (renin-inhibition), CANVAS (SGLT2-inhibition), RADAR (atrasentan), and BEACON (bardoxolone). Another interest is in determining the reasons for individual therapy resistance, and creating a response score to evaluate the effects of drugs. He has authored more than 440 international scientific publications and more than 60 book chapters, and has received the Lennart Hansson Memorial Lecture Award from the European Society of Hypertension, the International Distinguished Medal from the American National Kidney Foundation, and a special lecture award from the Japanese Society of Nephrology.